Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -174,523 | -124,137 | -72,950 | -32,024 | -60,011 |
| Depreciation Amortization | 492 | 283 | 117 | 32 | 9 |
| Accounts payable and accrued liabilities | 14,494 | 16,000 | 2,382 | 1,872 | 1,961 |
| Other Working Capital | 28,667 | 26,641 | 14,145 | 863 | -111 |
| Other Operating Activity | 13,828 | 4,429 | 11,455 | 7,222 | 27,423 |
| Operating Cash Flow | $-117,042 | $-76,784 | $-44,851 | $-22,035 | $-30,729 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -15,304 | -7,034 | -3,532 | -534 | -82 |
| Purchase Sale Intangibles | -6,250 | -6,000 | -5,500 | N/A | -9,000 |
| Other Investing Activity | -6,250 | -6,000 | -5,500 | 0 | -9,000 |
| Investing Cash Flow | $-21,554 | $-13,034 | $-9,032 | $-534 | $-9,082 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 39,957 | 29,978 | N/A | N/A | 1,673 |
| Debt Repayment | N/A | N/A | N/A | N/A | -1,673 |
| Common Stock Issued | N/A | N/A | N/A | N/A | 165,854 |
| Other Financing Activity | -874 | 0 | 0 | 0 | 125,210 |
| Financing Cash Flow | $39,083 | $29,978 | $0 | $N/A | $291,064 |
| Beginning Cash Position | 251,253 | 251,253 | 251,253 | 251,253 | N/A |
| End Cash Position | 151,740 | 191,413 | 197,370 | 228,684 | 251,253 |
| Net Cash Flow | $-99,513 | $-59,840 | $-53,883 | $-22,569 | $251,253 |
| Free Cash Flow | |||||
| Operating Cash Flow | -117,042 | -76,784 | -44,851 | -22,035 | -30,729 |
| Capital Expenditure | -15,304 | -7,034 | -3,532 | -534 | -82 |
| Free Cash Flow | -132,346 | -83,818 | -48,383 | -22,569 | -30,811 |